Table 2.
Phase I/II evidence for ICPis in advanced breast cancer.
| Author | n | Therapy | AE | ORR | PFS | OS |
|---|---|---|---|---|---|---|
| Emens et al., 2019 [56] | 116 TNBC |
Atezolizumab | 63% | 24% | 1.4 m | 17.6 m |
| Nanda et al., 2016 [57] | 31 TNBC |
Pembrolizumab | 66.3% | 18.5% | 1.9 m | 11.2 m |
| Adams et al., 2019 [55] | 170 TNBC |
Pembrolizumab | 60.6% | 5.3% | 2.0 m | 9.0 m |
| Adams et al., 2019 [47] | 84 TNBC |
Pembrolizumab | 63.1% | 21.4% | 2.1 m | 18.0 m |
| Adams et al., 2019 [66] | 33 TNBC |
Atezolizumab + nab-paclitaxel | 100% | 39.4% | 5.5 m | 14.7 m |
| Barroso-Sousa et al., 2020 [67] | 8 HR+ |
Pembrolizumab + radiotherapy | 87.5% | 0 | 1.4 m | 2.9 m |
| Pérez-García et al., 2020 [68] | 44 HR+ |
Pembrolizumab + eribulin | 18% | 6.0 m | - | |
| Yuan et al., 2021 [69] | 23 HR+ |
Pembrolizumab + palbociclib + letrozole | 56% | 25.2 m | 36.9 m |
Abbreviations: AE, adverse events; HR, hormine receptor; ICPis, immune checkpoint inhibitors; m, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TMBC, triple-negative breast cancer; vs., versus.